Abstract PO1-27-01: Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 Trial
Qingyuan Zhang(Qingdao University), Qingshan Li(Chengde Medical University), Nanlin Li(Xijing Hospital), Zhenhai Cai(Jiaxing University), Jing Sun(Nanchang University), Huihua Xiong(Tongji Hospital), Zhenhua Zhai(China Pharmaceutical University), Qiao Cheng(Medical College of Wisconsin), Antai Zhang(Guangdong Province Women and Children Hospital), Yanming Zhang(Guangdong Medical College), Shui Wang(Jiangsu Province Hospital), Yu Ren(Chongqing University), Hongwei Yang, Zhangjun Song(Shaanxi Provincial People's Hospital), Xinhong Wu(Hubei Cancer Hospital), Xinyu Qian(Hangzhou First People's Hospital), Fangling Ning(Binzhou Medical University), Xiao‐Hua Zeng, Caigang Liu(China Medical University), Jiuda Zhao(Qinghai University), Xiuheng Qi, Tao Sun(Wuhan University), Guoren Zhou(Jiangsu Cancer Hospital), Yonghui Luo(Nanchang University), Junyang Mo, Qun Su(Zhejiang University), Jie Hao(Nantong University), Lina Liu, Huijuan Wang, Wei Wang(Peking University), Zhihong Wang(Fudan University Shanghai Cancer Center), Shusen Wang(Sun Yat-sen University), Xiaobo Hu(Central South University), Liang Li(Peking University First Hospital), Xiaojia Wang(China Agricultural University), Enxiang Zhou(Central South University), Jiye Zhang(Xi'an Jiaotong University), Limin Wei(First Affiliated Hospital of Henan University of Science and Technology), Jianjun Huang(Shanghai Children's Hospital), Fuguo Tian(Shanxi Provincial Cancer Hospital), Yunjiang Liu(Hebei Medical University), Yuanqi Zhang(Guangdong Medical College), Dongning Chai, Xuchen Cao(Tianjin Medical University Cancer Institute and Hospital), Mingjiang Fan, Guozhong Cui(Cangzhou Central Hospital), Huadong Zhao, Dehong Zou(Zhejiang Cancer Hospital), Shuqun Zhang(Second Affiliated Hospital of Xi'an Jiaotong University)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner
|Oncogene|2019|265
Small molecule selenium-containing compounds: Recent development and therapeutic applications
|European Journal of Medicinal Chemistry|2021|233